Indevus Pharma Announces Additional Positive Phase III Trial Data For NEBIDO - Quick Facts

(RTTNews) - Indevus Pharmaceuticals Inc. (IDEV | news | PowerRating | PR Charts ) on Tuesday disclosed additional positive results from its Phase III program for NEBIDO or testosterone undecanoate, a long-acting injectable testosterone therapy under development for the treatment of male hypogonadism, a reduced or absent secretion of testosterone from the testes.

NEBIDO met its primary endpoints, a responder analysis based on average testosterone concentrations during the steady state dosing interval and an outlier analysis based on the maximum testosterone concentrations during the steady state dosing interval.

The company anticipates that the FDA Prescription Drug User Fee Act target action date for NEBIDO will remain June 27, 2008.

For comments and feedback: contact editorial@rttnews.com Copyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index